“Clarity Pharmaceuticals Ltd (CU6) is a clinical stage radiopharmaceutical company focused on the treatment of serious disease.

“The Company provides innovative radiopharmaceuticals, developing Targeted Copper Theranostics based on its SAR Technology Platform for the treatment of cancer in children and adults,” Michael said.

“Recent clinical trials have gone well, the company is well funded, and the stock has entered the ASX 300. “That inclusion saw some profit taking take place, but it now looks like the weakness is over and the shares are ready to continue on their stellar run.

“The stock had been trending well over the past several months, bouncing off the 50-day exponential moving average line (blue line).

“It recently fell under that, but we can see that spent the past several days tightening up sideways before breaking higher on Friday and following through to get back around the 50-day EMA.

“We expect CU6 to continue trending higher from here and current levels are a buying opportunity.

“An initial stop loss for traders can be considered back near the October low near $6.20,” Michael said.

Clarity Pharmaceuticals (CU6)

Important: This content has been prepared without taking account of the objectives, financial situation or needs of any particular individual. It does not constitute formal advice. Consider the appropriateness of the information in regard to your circumstances.